Genmab reported a largely in-line first quarter with revenue growth driven by solid execution across its proprietary portfolio, particularly EPKINLY and Tivdak, while maintaining development timelines and guidance; the stock was unchanged following the release.

• Total revenue increased 25% year-over-year, reflecting continued portfolio momentum.
• Proprietary product sales grew 43%, with EPKINLY up 52% to $137 million and Tivdak rising 18% to $39 million.
• The removal of hospitalization recommendation for EPKINLY in third-line DLBCL is expected to support broader outpatient use.
• Phase III RAINFOL-02 trial enrollment completed ahead of schedule, potentially accelerating data readout in platinum-resistant ovarian cancer.
• 2026 remains catalyst-rich with multiple Phase III trial readouts anticipated, supporting pipeline progression and potential new launches in 2027.